MedDataX Logo

Evaluation of Symbicort® Turbuhaler® (Budesonide/Formoterol) in Chronic Obstructive Pulmonary Disease (COPD)

NCT ID: NCT00837629

Last Updated: 2011-01-24

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

743 participants

Study Classification

OBSERVATIONAL

Study Start Date

2007-02-28

Study Completion Date

2007-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This non-interventional study is to analyse the therapeutic effectiveness in patients with severe COPD following a generally accepted 12-week treatment period with Symbicort Turbuhaler, which could anyhow be shortened or extended at physician's discretion.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Comparison of Symbicort® pMDI 2 x 160/4.5 μg Bid and 2 x 80/4.5 μg Bid With Formoterol Turbuhaler® 2 x 4.5 μg Bid and Placebo in Patients With COPD

NCT00206167

Chronic Obstructive Pulmonary Disease
COMPLETED PHASE3

Comparison Between Symbicort® and Prednisolone in COPD

NCT00259779

Chronic Obstructive Pulmonary Disease
COMPLETED PHASE3

Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary Disease

NCT02157935

COPD Patients
COMPLETED PHASE3

Study Comparing Dual Combination of Product (Budesonide and Formoterol) Given Via Two Different Inhalers. To See Which One Results in the Best Effect on Breathing.

NCT04078126

Chronic Obstructive Pulmonary Disease (COPD)
COMPLETED PHASE3

Symbicort in Chronic Obstruktive Pulmonary Disease

NCT00612976

Pulmonary Disease, Chronic Obstructive
COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Obstructive Pulmonary Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* non pregnant female
* COPD with persistent symptoms in spite of regular bronchodilator therapy
* Naive or fixed combination treated patients including patients already on Symbicort Turbuhaler

Exclusion Criteria

* Hypersensitivity to budesonide, formoterol or inhaled lactose
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

AstraZeneca

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

AstraZeneca

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Matjaz Flezar, MD

Role: PRINCIPAL_INVESTIGATOR

Golnik Hospital

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NIS-RSI-SYM-2006/1

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Efficacy and Safety Study of Symbicort® Turbuhaler® Versus Oxis® Turbuhaler® in Chronic Obstructive Pulmonary Disease (COPD) Patients
NCT01069289 COMPLETED PHASE3
Assess Particle Deposition and Acute Effects of Symbicort® Forte Turbohaler®) in COPD Patients.
NCT01329276 COMPLETED PHASE4
A Comparison of SYMBICORT® pMDI With Formoterol Turbuhaler® in Subjects With COPD
NCT00419744 COMPLETED PHASE3
Active Controlled Trial of CHF5993 Pressurized Metered-dose Inhaler ( pMDI) vs Symbicort®Turbuhaler® in Patients With Chronic Obstructive Pulmonary Disease ( COPD)
NCT03197818 COMPLETED PHASE3
Airway Clearance Study
NCT00379028 COMPLETED PHASE4
Symbicort Turbuhaler 30/60 Special Clinical Experience Investigation for Long-term Use for Chronic Obstructive Pulmonary Disease (COPD) Patients
NCT01713075 COMPLETED
Evaluation of Onset of Effect in Patients With Severe Chronic Obstructive Pulmonary Disease (COPD) Treated With Symbicort® Compared to Seretide®
NCT00542880 COMPLETED PHASE4
Evaluation of an Oxygen Enhanced Magnetic Resonance Imaging Method on Patients With Chronic Obstructive Pulmonary Disease During 8 Weeks Treatment With Either Symbicort Turbuhaler or Oxis Turbuhaler
NCT01257048 COMPLETED EARLY_PHASE1
Foster® pMDI (CHF 1535) Versus Symbicort® Turbohaler in COPD Patient
NCT03888131 COMPLETED PHASE3
Efficacy and Tolerability Study in Severe Chronic Obstructive Pulmonary Disease (COPD) Patients
NCT01415518 COMPLETED PHASE4
A Comparison of Symbicort® pMDI 2 x 160/4.5 μg Bid and Symbicort® pMDI 2 x 80/4.5 μg Bid With Formoterol Turbuhaler®, Budesonide pMDI, the Combination of Formoterol Turbuhaler® and Budesonide pMDI, and Placebo in COPD Patients
NCT00206154 COMPLETED PHASE3
Evaluate Onset of Effect in Patients With Chronic Obstructive Pulmonary Disease (COPD) Treated With Formoterol Turbuhaler®
NCT01048333 COMPLETED PHASE2
Comparative Effectiveness of Symbicort vs. Advair Among COPD Patients
NCT01921127 COMPLETED
Study to Assess Efficacy and Safety of PT009 Compared to PT005, PT008, and Symbicort® Turbuhaler® on Lung Function Over 24-Weeks in Subjects With Moderate to Very Severe COPD
NCT02766608 COMPLETED PHASE3
Symbicort in Chronic Obstructive Pulmonary Disease
NCT00611520 COMPLETED
To Confirm Equivalent Bronchodilator Efficacy of the Test Product Compared to the Reference Product
NCT02308098 COMPLETED PHASE3
A Safety and Efficacy Study of Symbicort Turbuhaler Compared With Standard Chronic Obstructive Pulmonary Disease (COPD) Treatment in Japan
NCT01070784 COMPLETED PHASE3
A Randomized, Double-Blind, Parallel-Group, 24-Week, Chronic-Dosing, Multi-Center Study to Assess the Efficacy and Safety of PT010, PT003, and PT009 Compared With Symbicort® Turbuhaler® (Kronos)
NCT02497001 COMPLETED PHASE3
Pharmacokinetic Pilot Study on Budesonide/Formoterol Device-metered Dry Powder Inhaler
NCT00868426 COMPLETED PHASE1
Efficacy and Safety Study of Symbicort Turbuhaler in Chinese Patients With COPD
NCT00421122 COMPLETED PHASE3
Evaluation of Efficacy on Exercise Tolerance of Symbicort (Budesonide/Formoterol) Compared to Placebo and Oxis in Patients With Severe COPD
NCT00489853 COMPLETED PHASE4
Study to Assess the Safety and Efficacy of PT010, PT003, and PT009 in Japanese Subjects With COPD Compared With Symbicort® Turbohaler®
NCT03262012 COMPLETED PHASE3
A Study to Investigate the Differential Effects of Inhaled Symbicort and Advair on Lung Microbiota
NCT02833480 UNKNOWN PHASE2
Changes in Cardiac Function in COPD Patients After Administration of Budesonide/Formoterol (Symbicort®) Versus Placebo
NCT01760304 TERMINATED PHASE4
Efficacy and Safety of Twice Daily 60mg AZD9668 in COPD for 12 Weeks in Patients on Background Budesonide/Formoterol
NCT01023516 COMPLETED PHASE2